{
  "abstract": "Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal stage of prostate cancer with poor prognosis. Clinical trials for mCRPC are growing rapidly worldwide. However, a comprehensive systematic analysis of the global research and development landscape in mCRPC remains lacking.\n\nMethods: This study queried the Trialtrove database for interventional trials in mCRPC registered between January 1, 2020 and March 27, 2026. After exclusion of unrelated trials and non-therapeutic studies, 474 trials were analyzed.\n\nResults: The therapeutic landscape for mCRPC has evolved into a highly diversified and dynamic field, overwhelmingly dominated by early-phase investigations. Targeted therapy, particularly PARP inhibitors, remain the leading class, while radiopharmaceutical therapy (RPT), centered on ¹⁷⁷ Lu-PSMA, has reached a mature stage of development. Immunotherapy is expanding beyond checkpoint blockade into bispecific T-cell engagers and cellular therapies, and endocrine therapy is being reshaped by PROTAC degraders. Antibody-drug conjugates (ADCs) are also gaining momentum, with B7 homolog 3 protein (B7-H3) as the most actively pursued targets. Combination regimens account for 39.2% of trials.\n\nConclusion: mCRPC clinical research landscape has diversified remarkably, shifting from conventional chemotherapy and endocrine therapy toward mechanism-based, biomarker-guided, and combination-oriented strategies.",
  "abstract_shown": true,
  "affiliations": [
    "Departments of Good Clinical Practice, Yaan People’s Hospital, Yaan , ,",
    "Department of Anesthesiology, Southwest Medical University, Luzhou , ,",
    "Departments of Pharmacy, Yaan People’s Hospital, Yaan , ,",
    "Department of Clinical Research Management, Affiliated Hospital of Southwest Medical University, Luzhou , ,"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Lin Fan"
    },
    {
      "affs": [
        1
      ],
      "name": "Shuang Wu"
    },
    {
      "affs": [
        2
      ],
      "name": "Xingxing Xie"
    },
    {
      "affs": [
        3
      ],
      "name": "Yang Zheng"
    },
    {
      "affs": [
        3
      ],
      "name": "Longxia Chen"
    },
    {
      "affs": [
        3
      ],
      "name": "Ruilin Ding"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3whcqp7nef12w.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1930401",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662642/?tool=EBI",
  "id": "3whcqp7nef12w",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13662642",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Prostate Cancer Treatment and Research"
    ]
  ],
  "openalex": "W7214979384",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662642/pdf/?tool=EBI",
  "pmcid": "PMC13662642",
  "pmid": null,
  "published": "2026-09-30",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/3whcqp7nef12w.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:20Z",
      "native_id": "PMC:PMC13662642",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13662642"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1930401",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1930401/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis",
  "title_text": "Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:13Z",
  "url": "https://research.draconitic.com/paper/3whcqp7nef12w",
  "venue": "Frontiers in oncology",
  "versions": []
}